Amlodipine and Olmesartan Medoxomil: What You Need to Know

Amlodipine and olmesartan medoxomil is a two-drug combination used to treat high blood pressure, pairing a calcium channel blocker (amlodipine) with an angiotensin receptor blocker (olmesartan). The combination works because the two drugs lower blood pressure through different pathways, and together they tend to produce larger drops in blood pressure than either drug alone. Available as both separate pills and a single fixed-dose tablet, this pairing has become one of the more commonly prescribed dual-therapy options for people whose blood pressure is not controlled on a single medication.

How the Two Drugs Work Together

Olmesartan blocks the effects of a hormone called angiotensin II at its receptor on blood vessels, preventing the hormone from tightening those vessels. Amlodipine works differently: it blocks calcium from entering the smooth muscle cells lining your arteries, which lets those muscles relax and the vessels widen. Because they act through separate mechanisms, combining them produces a complementary effect on blood pressure that is greater than what either achieves on its own.¹

There is a practical bonus to this pairing beyond the additive blood-pressure drop. Amlodipine on its own can cause ankle swelling because it dilates the small arteries feeding the lower legs without equally affecting the veins that drain them. Adding an angiotensin receptor blocker like olmesartan helps open those veins as well, which partially offsets the fluid buildup and reduces edema.² So the combination not only lowers blood pressure more effectively but can also ease one of amlodipine’s most annoying side effects.

How Much It Actually Lowers Blood Pressure

The landmark trial for this combination is the COACH study, a large randomized, double-blind, placebo-controlled trial that tested multiple dose combinations head-to-head against each drug alone and against placebo. The results showed clear dose-dependent drops in blood pressure: at the highest tested dose (olmesartan 40 mg/amlodipine 10 mg), average blood pressure fell by about 30/19 mmHg. Those reductions were significantly larger than what either drug produced on its own. By eight weeks, roughly half to just over half of patients on the higher combination doses had reached the standard blood pressure target of under 140/90 mmHg, compared with about 9% on placebo.³

A separate trial focused on people whose blood pressure was not well controlled on amlodipine alone. Adding olmesartan at doses of 10 to 40 mg on top of amlodipine 5 mg produced extra systolic drops of roughly 3.5 to 7 mmHg beyond what amlodipine alone achieved. When patients who still were not at goal had their doses increased over time, more than 70% reached their blood pressure target by week 24.⁴ These numbers matter because they describe exactly the scenario many patients find themselves in: one drug is helping, but not enough.

Benefits Beyond Blood Pressure Numbers

Blood pressure readings are the primary reason to prescribe this combination, but several studies suggest it also improves the health of your blood vessels in ways that a simple blood pressure number does not capture. A trial in African-American patients with cardiometabolic risk factors found that olmesartan/amlodipine reduced pressure inside the central aorta by about 42% and lowered arterial stiffness (measured by pulse wave velocity) by about 22%. A different combination of losartan and hydrochlorothiazide produced smaller improvements in both measures, despite similar drops in standard blood pressure readings.⁵

Central aortic pressure is the pressure your heart and brain actually “feel,” and it can differ meaningfully from the reading you get with an arm cuff. A randomized, double-blind trial directly comparing olmesartan/amlodipine against perindopril/amlodipine found the olmesartan combination lowered central systolic blood pressure by about 14.5 mmHg versus 10.4 mmHg for the perindopril combination, a difference of roughly 4 mmHg that was statistically significant.⁶ Whether these differences translate into fewer heart attacks and strokes over the long run is still being studied, but the direction of the evidence is encouraging.

Who It Works For

One reassuring finding across trials is that the combination seems to work broadly. A review of data from multiple studies found that the efficacy and tolerability of olmesartan plus amlodipine was not meaningfully affected by age, gender, severity of hypertension, diabetes status, race, or body mass index.⁷ That is a useful piece of information in a field where many drugs perform differently depending on the patient population.

In elderly patients, including those with isolated systolic hypertension (where only the top number is elevated), olmesartan has shown solid results. In one trial, average systolic blood pressure dropped by about 30 mmHg at 12 weeks, and roughly 63% of patients reached their systolic target by 24 weeks. Dose increases and add-on therapy were well tolerated.⁸

For patients with diabetes and obesity, a study using 24-hour ambulatory blood pressure monitoring (which captures what happens while you sleep and go about your day, not just during a clinic visit) showed average drops of about 21–22 mmHg systolic. Around 75–79% of patients with diabetes or obesity reached the stricter 24-hour ambulatory target of under 130/80 mmHg.⁹

Metabolic Advantages Over Other Combinations

If you have metabolic syndrome, your doctor’s choice of second blood pressure drug matters beyond just blood pressure control. The OLAS study compared olmesartan/amlodipine against olmesartan/hydrochlorothiazide (a diuretic) in patients with metabolic syndrome. Both combinations lowered blood pressure effectively, but only the amlodipine combination reduced insulin resistance (by about 24%), raised adiponectin (a protective fat-tissue hormone, by about 16%), and significantly lowered most markers of inflammation. Patients on the amlodipine combination also had a significantly lower risk of developing new-onset diabetes.¹⁰

These findings are consistent with broader guideline recommendations. Agents that block the renin-angiotensin system, paired with a calcium channel blocker, are generally preferred over combinations involving a diuretic in patients with metabolic complications, because diuretics can worsen blood sugar control and raise uric acid levels.¹¹

Side Effects You Should Know About

The combination is generally well tolerated. In the COACH trial, the most common side effects at various doses were dizziness, headache, and peripheral edema (ankle swelling). Most were mild or moderate. As mentioned earlier, the edema is usually less pronounced with the combination than with amlodipine alone, because olmesartan partially counteracts the mechanism behind it.

There is, however, a rare but serious side effect specific to olmesartan that is worth knowing about: a condition sometimes called sprue-like enteropathy. This involves severe, chronic diarrhea and significant weight loss (a median of about 18 kg in reported cases), along with nausea, fatigue, and sometimes dehydration bad enough to require hospitalization. It can develop months or even years after starting olmesartan, which makes it tricky to diagnose. Biopsies of the small intestine show damage that looks very similar to celiac disease, but standard celiac blood tests come back negative.¹²

A systematic review of published cases found that nearly all patients presented with diarrhea and weight loss, and 98% had villous atrophy on intestinal biopsy. The encouraging part: after stopping olmesartan, all reported patients recovered completely.¹³ The condition is thought to be rare, though the exact incidence is unclear.¹⁴ If you develop persistent, unexplained diarrhea while taking olmesartan, bring it up with your doctor rather than assuming it is unrelated. The long delay between starting the medication and developing symptoms is what causes many cases to be missed.

The Fixed-Dose Pill and Why It Matters for Adherence

Taking two blood pressure medications means two pills, two refills, and twice the opportunity to forget one. This is not a minor concern. Poor adherence is one of the main reasons blood pressure stays uncontrolled, and studies consistently show that combining drugs into a single tablet makes a real difference.

An Italian study tracked patients who switched from taking the two drugs separately to a fixed-dose combination tablet. Adherence jumped from about 59% to nearly 79% after the switch. Patients who stayed on the separate pills also improved somewhat over the same period (from about 56% to 63%), but the fixed-dose group’s gain was much larger.¹⁵ A separate study found an even more dramatic gap: at six months, 55% of patients on the fixed-dose tablet were adherent versus only about 16% of those taking the two pills separately. After adjusting for other factors, the fixed-dose group was roughly six to seven times more likely to be adherent.¹⁶

These adherence gains are not just academic. Better adherence means more consistent blood pressure control, which over years translates into fewer cardiovascular events. The fixed-dose tablet delivers the same drug exposure as taking the two drugs separately, as confirmed by pharmacokinetic studies showing the two approaches are bioequivalent.¹⁷ One practical note: there is evidence that olmesartan absorption drops after a high-fat meal, even though amlodipine absorption is unaffected by food.¹⁸ Whether to take it with or without food is worth asking your prescriber about, especially if your blood pressure control seems inconsistent.

When Two Drugs Are Not Enough

Some patients need three medications to get their blood pressure under control, and a natural step-up from olmesartan/amlodipine is to add a low-dose diuretic. The TRINITY trial tested exactly this, randomizing patients to either the triple combination (olmesartan 40 mg, amlodipine 10 mg, and hydrochlorothiazide 25 mg) or one of three possible two-drug pairings from those same drugs. At 12 weeks, the triple combination dropped systolic blood pressure by about 37 mmHg versus 27.5–30 mmHg for the dual therapies. About 70% of the triple-combination group reached the 140/90 target, compared with 41–53% of the dual-therapy groups.¹⁹

Ambulatory blood pressure monitoring in a subset of TRINITY patients confirmed that the triple combination’s advantage held throughout the full 24-hour period, including during nighttime and the last few hours before the next dose, when many medications are running out of steam.²⁰ Side effects in the triple group were similar in severity to the dual groups, though slightly more patients discontinued treatment (4% versus 1–2%). Dizziness and peripheral edema were the most commonly reported issues.

Morning Versus Bedtime Dosing

For years, there has been debate about whether blood pressure medications work better when taken at night. Most people’s blood pressure dips while they sleep, but in a large subset of hypertensive patients it does not, a pattern called “non-dipping” that is linked to higher cardiovascular risk. A recent randomized trial (the OMAN trial) specifically tested morning versus bedtime dosing of the olmesartan/amlodipine combination. Patients who took the combination at bedtime had significantly greater reductions in nighttime systolic blood pressure, with about a 3 mmHg advantage over the morning group. Nighttime systolic control (getting below target while asleep) was achieved by 79% of the bedtime group versus about 70% of the morning group.²¹

A smaller crossover study in patients specifically identified as non-dippers found that bedtime dosing of this combination corrected the nocturnal blood pressure pattern without causing excessive drops in people who already had a normal nighttime dip. It also reduced the early-morning blood pressure surge, which is the sharp rise in blood pressure that occurs around waking and is associated with strokes and heart attacks in the morning hours. Additionally, urinary albumin excretion (a marker of kidney stress) improved with bedtime dosing.²² If your doctor has identified you as a non-dipper through ambulatory monitoring, bedtime dosing of this combination is a conversation worth having.

Quality of Life on the Combination

Blood pressure medications sometimes get blamed for making people feel worse, and that perception drives a lot of non-adherence. A large observational study in primary care assessed quality of life using a standard health questionnaire before and after switching patients to the olmesartan/amlodipine fixed-dose tablet. All 12 measured domains improved significantly, with both physical and mental health summary scores increasing. Physical scores rose from about 40 to 47, and mental scores from about 47.5 to 52.4.²³ Part of that improvement likely reflects better blood pressure control itself (chronically high blood pressure can cause fatigue, headaches, and poor concentration), and part may reflect the simplicity of a single-pill regimen replacing a more complicated one.

Cost Considerations

A health-economic analysis modeled the long-term costs and outcomes of several blood pressure treatment strategies in China. Compared with taking olmesartan and amlodipine as two separate pills, the fixed-dose combination tablet resulted in fewer cardiovascular events and deaths over time while actually costing less per patient, making it what economists call “dominant” (better outcomes, lower cost). When compared with the valsartan/amlodipine fixed-dose combination, it was also dominant. Against amlodipine monotherapy, the fixed-dose combination cost modestly more but produced substantially greater health gains.²⁴ These results come from one country’s pricing structure and healthcare system, so they will not directly translate everywhere, but the general principle holds: better adherence from a single pill tends to produce better outcomes and offset its upfront cost through fewer hospital visits and cardiovascular events down the road.

Olmesartan and Organ Protection

Beyond blood pressure, olmesartan has been studied for potential protective effects on the heart, blood vessels, and kidneys. Trials have shown improvements in markers like microalbuminuria (small amounts of protein leaking into the urine, an early sign of kidney damage), regression of artery wall thickening, and reductions in plaque volume and microinflammation.²⁵ When paired with amlodipine, these organ-protective effects sit alongside the vascular and metabolic benefits discussed earlier, making the combination a reasonable choice for patients whose hypertension coexists with early signs of target-organ damage. Whether these surrogate improvements fully translate into fewer clinical events like heart attacks and strokes over decades is the kind of question that requires very large, long-running trials, and the answer is still being refined. But for now, the signals point in the right direction.